Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
9.28
-0.03 (-0.32%)
At close: Oct 12, 2026, 4:00 PM EDT
9.94
+0.66 (7.11%)
Pre-market: Oct 13, 2026, 9:18 AM EDT
Gossamer Bio Employees
As of December 31, 2025, Gossamer Bio had 162 total employees, including 161 full-time and 1 part-time employees. The number of employees increased by 17 or 11.72% compared to the previous year. That makes Gossamer Bio the 28,261st largest employer in the world and 3,585th in the United States.
Employees
162
Change (1Y)
17
Growth (1Y)
11.72%
Revenue / Employee
$328,926
Profits / Employee
-$772,981
Market Cap
56.76M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 162 | 17 | 11.72% | 161 | 1 |
| Dec 31, 2024 | 145 | 10 | 7.41% | 144 | 1 |
| Dec 31, 2023 | 135 | -43 | -24.16% | 135 | 0 |
| Dec 31, 2022 | 178 | -7 | -3.78% | 178 | 0 |
| Dec 31, 2021 | 185 | -11 | -5.61% | 185 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fractyl Health | 100 |
| Clene | 79 |
| Connect Biopharma Holdings | 64 |
| Mereo BioPharma Group | 39 |
| Boundless Bio | 28 |
| iBio, Inc. | 23 |
| RenovoRx | 17 |
| Alterity Therapeutics | 11 |
GOSS News
- 4 hours ago - Gossamer Bio initiated with a Buy at Chardan - TheFly
- 19 days ago - Gossamer Bio submits New Drug Application to FDA for seralutinib - TheFly
- 19 days ago - Gossamer Bio submits New Drug Application to FDA for seralutinib - TheFly
- 19 days ago - Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension - Business Wire
- 22 days ago - Gossamer Bio target adjusted to $90 for split at H.C. Wainwright - TheFly
- 26 days ago - Gossamer Bio Appoints Greg Ciongoli to Board of Directors - Business Wire
- 27 days ago - Gossamer Bio Proxy statement: Proxy filing - Filings
- 4 weeks ago - Gossamer Bio announces effectiveness of 1-for-80 reverse stock split - TheFly